Depot antipsychotics: If you pay me, you can keep injecting me


John Baker looks at the 2-year follow-up results of a cluster RCT on the effectiveness of financial incentives to improve adherence to maintenance treatment with depot antipsychotics.

[read the full story...]

Bipolar disorder in older men linked to increased risk of dementia


Elena Marcus presents a recent study that shows how older Australian men with bipolar disorder have an increased risk of dementia and early death.

[read the full story...]

The side-effects of antipsychotics: let’s systematically assess, discuss and act! #NPNR2016


A live blog published at the 22nd International Network for Psychiatric Nursing Research conference in Nottingham.

Written by John Baker, Lucy Brazener, Wendy Cross, Vanessa Garrity, Andrew Grundy, Cher Hallett, Ben Hannigan, Elaine Hanzak and Alan Simpson.

[read the full story...]

It’s a jungle out there: the natural history of behavioural and psychological symptoms of dementia


Caroline Struthers scrutinises a systematic review on the longitudinal course of behavioural and psychological symptoms of dementia.

[read the full story...]

Schizophrenia, antipsychotics and quality of life: measuring the important things


Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.

[read the full story...]

Adding antidepressants to antipsychotics in schizophrenia: do they work, for what, and are they safe?


Alex Langford explores the emerging findings from a recent meta-analysis looking at the efficacy and safety of antidepressants added to antipsychotics for people with schizophrenia and schizophrenia-like psychosis.

[read the full story...]

ITI-007 for schizophrenia


Murtada Alsaif summarises a recent 4-week long phase II randomised controlled trial of ITI-007 for the treatment of schizophrenia, which contains some positive results for this novel intervention.

[read the full story...]

Evidence-based guidelines for treating bipolar disorder


Joseph Hayes summarises the recent British Association for Psychopharmacology guidelines for the treatment of bipolar disorder, and compares their recommendations with those found in the NICE bipolar disorder guidance from 2014.

[read the full story...]

Trends in antipsychotic prescribing in autism


Angela Hassiotis and James Dove summarise a recent meta-analysis of antipsychotic prescribing and use trends in US youth with autism spectrum disorder and/or learning disabilities.

[read the full story...]